Desarrollo, Producción e Innovación en la Investigación científica

Permanent URI for this communityhttp://48.217.138.120/handle/20.500.12272/2392

Browse

Subject: search.filters.subject.LP-SBA-15

Search Results

Now showing 1 - 6 of 6
  • Thumbnail Image
    Item
    LP-SBA-15/Ketorolac Nanocomposite: Development, Characterization, and Mathematical Modeling of Controlled Keto Release.
    (Univesidsad Tecnológica Nacional, 2023) Cussa, jorgelina; Juárez , Juliana María; Gómez Costa, Marcos Bruno; Anunziata, Oscar Alfredo
    Drug-controlled release systems can keep the level of drugs in precise doses in the body above the optimal level and with low toxicity. We propose the nanomaterial LP-SBA-15 as an attractive new host for drug delivery systems due to its high biocompatibility, in vivo biodegradability, and low toxicity. LP-SBA-15/Ketorolac was prepared and characterized by XRD, FTIR, UV-Vis DRS, TEM, and texture analysis, determining the adsorption capacity and its release and achieving the required therapeutic efficacy. The host shows the ordered mesoporous nanochannels with a diameter of 11-12 nm, maintaining the structure with the incorporation of Keto. The mechanism of drug release from the LP-SBA-15 host was evaluated. Different mathematical models were used to adjust the experimental data, the Ritger-Peppas model followed by the Weibull model the best ones. The promising results we obtained for the release of the drug thoroughly using the new material, reaching a rapid initial release rate, and maintaining a constant rate afterward, allow us to maintain the concentration of the drug in the therapeutic efficacy range, applying it largely to the treatment of diseases that require a rapid response.
  • Thumbnail Image
    Item
    LP-SBA-15, functionalized with tert-butylamine a novel controlled release system for cyclophosphamide.
    (Univesidsad Tecnológica Nacional, 2013) Juárez , Juliana María; Cussa, Jorgelina; Gómez costa , Marcos Bruno; Anunziata, Oscar Alfredo; Anunziata, Oscar Alfredo
    Controlled drug administration systems can keep the level of drugs in specific locations in the organism with low toxicity and above the optimal level. We suggest the LP-SBA-15 material as an auspicious new host for drug delivery systems because of its low toxicity high biocompatibility and in vivo biodegradability. LP SBA-15 materials were synthesized and functionalized using 0-15-30% of tert butylamine (TBA) and used as effective drug delivery systems. The anticancer drug Cyclophosphamide (CP) is an alkylating compound which is a phosphoramide derivative and is habitually used in autoimmune diseases. Reactive oxygen species production has been related to the mechanism of CP-induced cell death or tumor cell killing. The activated metabolites of CP are released in both healthy and tumor tissues and destroy the cellular DNA and proteins as well as mitochondrial and lysosomal membranes. CP was loaded into the nanomaterial of the transporters and characterized by XRD, FTIR, TGA, TEM and texture, determining the adsorption capacity and its release. The release of the drug was studied for each material by simulating the physiological conditions and submerging the composite, at 37 °C with constant stirring, in a HCl solution (0.1 M) for the first two hours and in Buffer solution pH = 7 the following hours to simulate the conditions of the organism. Release experiment were conducted to determine the requisite efficacy of treatment. The study was performed by UV-Vis spectrophotometry to evaluate the amount of CP released. The mechanism of drug release from the LP-SBA-15 matrix was evaluated by adjusting the experimental data, being the Ritger-Peppas (figure 1) The promising results we obtained for the controlled release of the drug in a controlled manner using the new material, reaching a quick initial release rate and maintaining a constant rate at high moments, allow us to keep the concentration of the drug in the therapeutic efficacy range, applying it to a great extent to the treatment of diseases that require a rapid response. Lastly, it was suggested that the LP-SBA-15 nanomaterial functionalized with 15% TBA was the most desirable system due to they had adequate amounts of both drug loading and release
  • Thumbnail Image
    Item
    Large pore SBA-15 functionalized as drug carrier of Cyclophosphamide.
    (Univesidsad Tecnológica Nacional, 2023) Juárez , Juliana María; Cussa, Jorgelina; Anunziata, Oscar Alfredo; Gómez Costa, Marcos Bruno
    Controlled drug administration systems can keep the level of drugs in specific locations in the organism with low toxicity and above the optimal level. We suggest the LP-SBA-15 material as an auspicious new host for drug delivery systems because of its low toxicity high biocompatibility and in vivo biodegradability. LP-SBA-15 materials were synthesized and functionalized using 0-15-30% of tert-butylamine (TBA) and used as effective drug delivery systems. The anticancer drug Cyclophosphamide (CP) is an alkylating compound which is a phosphoramide derivative and is habitually used in autoimmune diseases. Reactive oxygen species production has been related to the mechanism of CP-induced cell death or tumor cell killing. The activated metabolites of CP are released in both healthy and tumor tissues and destroy the cellular DNA and proteins as well as mitochondrial and lysosomal membranes. CP was loaded into the nanomaterial of the transporters and characterized by N2 adsorption-desorption, Ultraviolet-visible diffusereflectance spectroscopy (UV-Vis DRS), FTIR, determining the adsorption capacity and its release. The release of the drug was studied for each material by simulating the physiological conditions and submerging the composite, at 37 °C with constant stirring, in a HCl solution (0.1 M) for the first two hours and in Buffer solution pH = 7 the following hours to simulate the conditions of the organism. Release experiments were conducted to determine the requisite efficacy of treatment. The study was performed by UV-Vis spectrophotometry to evaluate the amount of CP released. The mechanism of drug release from the LP-SBA-15 functionalized matrix was evaluated by adjusting the experimental data, being the Ritger-Peppas model, Weibull model and First-Order model, the best models to adjust the experimental data is the, which is confirmed by the R2 coefficient of determination. The promising results we obtained for the controlled release of the drug in a controlled manner using the new material, reaching a quick initial release rate and maintaining a constant rate at high moments, allow us to keep the concentration of the drug in the therapeutic efficacy range, applying itto a great extent to the treatment of diseases that require a rapid response. Lastly, it was suggested thatthe LP SBA-15 nanomaterial functionalized with 15% TBA was the most desirable system due to they had adequate amounts of both drug loading and release
  • Thumbnail Image
    Item
    LP-SBA-15/ketorolac nanocomposite: development, characterization, and mathematical modeling of controlled keto release
    (2022) Cussa, Jorgelina; Juárez, Juliana María; Gómez Costa, Marcos Bruno; Anunziata, Oscar Alfredo
    Drug-controlled release systems can keep the level of drugs in precise doses in the body above the optimal level and with low toxicity. We propose the nanomaterial LP-SBA-15 as an attractive new host for drug delivery systems due to its high biocompatibility, in vivo biodegradability, and low toxicity. LP-SBA-15/Ketorolac was prepared and characterized by XRD, FTIR, UV-Vis DRS, TEM, and texture analysis, determining the adsorption capacity and its release and achieving the required therapeutic efficacy. The host shows the ordered mesoporous nanochannels with a diameter of 11-12 nm, maintaining the structure with the incorporation of Keto. The mechanism of drug release from the LP-SBA-15 host was evaluated. Different mathematical models were used to adjust the experimental data, the Ritger-Peppas model followed by the Weibull model the best ones. The promising results we obtained for the release of the drug thoroughly using the new material, reaching a rapid initial release rate, and maintaining a constant rate afterward, allow us to maintain the concentration of the drug in the therapeutic efficacy range, applying it largely to the treatment of diseases that require a rapid response.
  • Thumbnail Image
    Item
    Síntesis, caracterización y aplicación del nanomaterial lp-sba-15 en la liberación controlada de ketorolac trometamina
    (2020) Juárez, Juliana M.; Gómez Costa, Marcos B.; Cussa, Jorgelina
    Los sistemas controlados de administración de fármacos pueden mantener la concentración de medicamentos en los sitios exactos del cuerpo dentro del rango óptimo y por debajo del umbral de toxicidad, mejorando la eficacia terapéutica y reduciendo la toxicidad. El material LP-SBA-15 es un nuevo huésped prometedor para los sistemas de administración de fármacos debido a su alta biocompatibilidad, biodegradabilidad in vivo y baja toxicidad. Se sintetizó el composite ketorolac-trometamina/LP-SBA-15. La síntesis del material y la carga de ketorolac-trometamina en los poros LP-SBA-15 fue exitosa, como lo demuestran los análisis XRD, FTIR, TGA, TEM y análisis morfologicos. Obtuvimos resultados prometedores para la liberación controlada de fármacos utilizando el nuevo material. La aplicación de estos materiales en la liberación de KETO es innovadora, logrando una alta tasa de liberación inicial y luego manteniendo una liberación más lenta. Esto permite mantener la concentración del fármaco dentro del rango de eficacia terapéutica, siendo altamente aplicable para el tratamiento de enfermedades que necesitan una respuesta rápida.
  • Thumbnail Image
    Item
    Preparation, characterization and mathematical modeling of keterolac release conteined in lpsba-15 host
    (2021) Cussa, Jorgelina; Juárez, Juliana M.; Gómez Costa, Marcos B.; Anunziata, Oscar A.
    Drug-controlled release systems can keep the level of drugs in precise doses in the body above the optimal level and with low toxicity. We propose the LP-SBA-15 nanomaterial as a promising new host for drug delivery systems because of its high biocompatibility, in vivo biodegradability, and low toxicity. Ketorolac-LP-SBA-15 was prepared and characterized by XRD, FTIR, UV-Vis DRS, TEM, and texture analysis, determining the adsorption capacity and its release, achieving the required therapeutic efficacy. The host shows ordered mesoporous nanochannels with a diameter of 11-12 nm, maintaining the structure with the incorporation of Keto. The mechanism of drug release the LP-SBA-15 host was evaluated. Different mathematical models were used to adjust the experimental data, being the Ritger-Peppas model followed by the Weibull model the best ones. In this work, we show a promising drug storage material for effective encapsulation and controlled release of KETO, achieving the required therapeutic efficacy. Studies indicate that KETO was adsorbed on the channel surface of LP-SBA-15 without affecting the structure or chemical composition of KETO. Controlled drug delivery systems can achieve precise delivery at the time and place of destination, keeping the concentration of the drug at points in the body within the optimal range and below the toxicity threshold. The study also demonstrates the storage capacity and release properties of LPSBA- 15 containing KETO. The release of KETO contained in LP-SBA-15 can offer a significant improvement in the controlled release of the drug and the analgesic and anti-inflammatory effects, positively influenced, by the links formed between the host and drug molecules and by diffusion through the host porosity. The promising results we obtained for the release of the drug thoroughly using the new material, reaching a rapid initial release rate, and maintaining a constant rate afterward, allow us to maintain the concentration of the drug in the therapeutic efficacy range, applying it largely to the treatment of diseases that require a rapid response.